Condition: Non-small Cell Lung Cancer Stage III · KRAS P.G12C · Sponsor: Fundación GECP
Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 months.
This description comes directly from the study's public registry record.
Eva Pereira · 934302006 · gecp@gecp.org
Always discuss trial participation with your own doctor first.
| Hospital General Universitario de Alicante | Alicante, Alicante, Spain | Recruiting |
| ICO Badalona, Hospital Germans Trias i Pujol | Badalona, Barcelona, Spain | Recruiting |
| Hospital Universitari Quiron Dexeus | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Universitari Vall d' Hebron | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Parc Taulí | Barcelona, Barcelona, Spain | Recruiting |
| Hospital De Basurto | Bilbao, Bilbao, Spain | Recruiting |
| ICO Girona, Hospital Josep Trueta | Girona, Girona, Spain | Recruiting |
| Hospital Clínico San Cecilio De Granada | Granada, Granada, Spain | Recruiting |
| Complejo Hospitalario De Jaén | Jaén, Jaén, Spain | Recruiting |
| Hospitalario Universitario A Coruña | A Coruña, La Coruña, Spain | Recruiting |
| Hospital Universitario Lucus Augusti | Lugo, Lugo, Spain | Recruiting |
| Hospital Universitario Severo Ochoa | Leganés, Madrid, Spain | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05398094